An observational study in Thyroid Nodule and Thyroid Cancer, sponsored by University of Cagliari. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-23.
Sponsored by University of Cagliari · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Thyroid Nodule with a site in Italy — 6 open to participants now, 6 under way, none of them phase 3. Thyroid Nodule · Italy.
Among the 11 studies in Thyroid Nodule with a site in Italy, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 5th registered.
208 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.
Browse Thyroid Nodule studies →6 of the 11 studies in Thyroid Nodule with a site in Italy are open now. Recruiting first, the newest first:
Regina Elena Cancer Institute · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
Istituto Auxologico Italiano · Sites in Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 43 Thyroid Nodule studies recruiting now, 33 (77%) set no upper age limit and 5 (12%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 161 across 82 observational studies indexed under Thyroid Nodule.
Median enrollment 30 across the 7 interventional studies, 236 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of Cagliari has 1 study filed under Thyroid Nodule — fewer than ten, so there is no comparison to draw.
2 of the studies in Thyroid Nodule with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736015Regina Elena Cancer InstituteMyo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a) | 2027-03-18 |
| NCT05428371University of CagliariAssessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Thyroid Nodule with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.
We plan to include in our study patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda classification) who have a mild risk of thyroid cancer (15-30%)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with indeterminate thyroid nodule and pathological diagnosis of thyroid carcinoma
Diagnostic Test: Multiomic analyses of blood and surgical specimens
Patients with indeterminate thyroid nodule and pathological diagnosis of follicular adenoma
Diagnostic Test: Multiomic analyses of blood and surgical specimens
The following items will be evaluated: * cell free dna length and integrity * presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples * qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)
Identification of biomarkers of thyroid carcinoma
Identification of alterations in cfDNA length and integrity, presence of SNPs in cfDNA, alterations of serum proteome predictive of thyroid carcinoma
Time frame: 50 months
Elaboration of diagnostic algorithm
Elanoration of diagnostic algorithm predictive of thyroid carcinoma through integration of clinical, ultrasonographic and multiomic variables able to predict che condition of thyroid cancer in patients with indeterminate thryoid nodules
Time frame: 60 months
Plan to share: Undecided — Individual participant data will be available under reasonable request
No publications or documents are linked to this record.
Start is estimated for Jan 2023; primary completion for May 2027, 52 months later.
Of 38 observational studies under Thyroid Nodule, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32. This study's planned 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Cagliari